朗迪Reneed品牌怎么样 申请店铺

我要投票 朗迪Reneed在补钙行业中的票数:14 更新时间:2024-11-22
朗迪Reneed是哪个国家的品牌?「朗迪Reneed」是 北京振东康远制药有限公司 旗下著名品牌。该品牌发源于北京市,由创始人李昆在2003-11-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
朗迪Reneed怎么样

钙营养补充剂品牌,主打维生素矿物质钙补充剂类药物,集研发、生产、销售于一体的集团化现代综合制药企业


北京振东康远制药有限公司始建于2003年10月,是国内较大的具有自主品牌的维生素矿物质钙补充剂类药物生产企业,是一家集研发、生产、销售于一体的集团化现代综合制药公司,是中国补钙药物的佼佼者和先锋。公司产品遍布全国,公司“朗迪”牌碳酸钙D3片(II)和碳酸钙D3颗粒已成为中国钙补充剂类药品市场的主流。公司2015年与上市公司振东集团山西振东制药股份有限公司强强联合,完成重大重组,实现了跨跃式发展。

公司于2009年进入中国钙制剂市场,旗下现有7家直属或控股的制药公司、2家直属药物研发公司及多家医药贸易公司,在30多个城市设立了办事机构,有数千家合作伙伴,累计总投资超过10亿元,全国有数千名员工为康远工作。

公司位于北京市昌平区西部约15公里的北京市昌平区流村工业园内,隶属中关村科技园昌平园。该厂区自2012年开始建造,总投资近亿元,按照新版欧盟GMP标准及中国GMP标准进行规划、设计和建设施工,配有国际前沿的制粒、干燥、混合、压片、包装等片剂、硬胶囊剂、颗粒剂生产线及软胶囊剂生产线,该项目已于2014年通过了BFDA组织的GMP认证,并获得片剂、硬胶囊剂、颗粒剂、软胶囊剂GMP证书。项目年生产能力近百亿片(粒、袋)。该项目的建成使康远制药一跃成为国内维生素矿物质钙补充剂类药物较大生产企业。

公司发展过程中始终以“构建国人健康骨骼”为已任,以“树民族工业品牌,为中国制药争光”为使命,为中国钙制剂的发展做出了较大的贡献,大大改善了亿万国人的生活质量。康远人负有共同的使命,遵循一致的价值观,始终秉承“济世安康、立勋鸿远”宗旨来服务社会、回报社会。目前公司年营业收入达数十亿元,年上缴税金数亿元。随着公司高速发展和对未来中国经济和全球钙制剂市场发展前景充分信心,北京振东康远制药正不断加快创新、运筹帷幄、酝酿百年规划,未来的康远终将成为一家拥有精良技术和设备、管理成熟的世界制药公司。


Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd., a brand of calcium supplements, is a group modern comprehensive pharmaceutical enterprise integrating R & D, production and sales. It was founded in October 2003. It is a large domestic manufacturer of vitamin and mineral calcium supplements with its own brand, integrating R & D, production and sales Group modern comprehensive pharmaceutical company is the leader and pioneer of calcium supplements in China. The company's products are all over the country, and its "landi" brand calcium carbonate D3 tablets (II) and calcium carbonate D3 particles have become the mainstream of China's calcium supplements market. In 2015, the company and the listed company Zhendong Group Shanxi Zhendong Pharmaceutical Co., Ltd. jointly completed major restructuring and achieved a leap forward development. In 2009, the company entered the calcium preparation market in China. At present, it has 7 pharmaceutical companies directly under or controlled by the company, 2 pharmaceutical research and development companies directly under the company and many pharmaceutical trading companies. It has set up offices in more than 30 cities, thousands of partners, with a total investment of more than 1 billion yuan, and thousands of employees working for Kangyuan. The company is located in Liucun Industrial Park, Changping District, Beijing, about 15km away from the west of Changping District, Beijing. The plant has been constructed since 2012, with a total investment of nearly 100 million yuan. It is planned, designed and constructed in accordance with the new version of EU GMP standard and China GMP standard. It is equipped with internationally cutting-edge tablet, hard capsule, granule production line and soft capsule production line. The project has passed the GMP certification organized by bfda in 2014, and has obtained tablet GMP certificate of hard capsule, granule and soft capsule. The annual production capacity of the project is nearly 10 billion pieces (grain and bag). With the completion of the project, Kangyuan pharmaceutical has become a large domestic manufacturer of vitamin, mineral and calcium supplements. In the development process of the company, we always take "building healthy skeleton of Chinese people" as our responsibility, take "building national industrial brand, winning honor for Chinese pharmaceutical" as our mission, and have made great contribution to the development of Chinese calcium preparation, greatly improving the quality of life of hundreds of millions of Chinese people. Kangyuan people have a common mission, follow the same values, and always adhere to the tenet of "helping the world and health, and making contributions to Hongyuan" to serve and repay the society. At present, the company's annual operating revenue is billions of yuan, and the annual tax payment is hundreds of millions of yuan. With the rapid development of the company and full confidence in the future development of China's economy and the global calcium preparation market, Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd. is constantly accelerating innovation, strategizing and brewing a hundred year plan. In the future, Kangyuan will eventually become a world pharmaceutical company with excellent technology and equipment and well managed.

本文链接: https://brand.waitui.com/52bc17e3b.html 联系电话:01056940619

千城特选小程序码

7×24h 快讯

李彦宏:百度文库AI功能月活用户超5000万,同比增长超300%

36氪获悉,百度2024年第三季度财报电话会上,百度创始人、董事长兼首席执行官李彦宏披露,今年9月,百度文库AI功能月活用户突破5000万,同比增长超300%。此外,用户的付费意愿不断增强,第三季度文库的订阅收入同比增长23%。在近期举办的百度世界2024上,百度文库与百度网盘联合推出了工具类智能体“自由画布”,亮相首日即吸引超20万人排队预约。

12分钟前

李彦宏:Q3智能云营收快速增长,AI收入占比提升至超11%

36氪获悉,在百度2024年第三季度财报电话会上,百度创始人、董事长兼首席执行官李彦宏公布,三季度,百度智能云营收达49亿元,同比增长11 %,Non-GAAP 经营利润率同比提升。其中,AI相关收入占比持续提升至超11%。据IDC报告,在中国AI公有云市场,百度智能云已连续五年位居第一。

12分钟前

热门中概股美股盘前普跌,拼多多跌超10%

36氪获悉,热门中概股美股盘前普跌,截至发稿,拼多多跌超10%,小鹏汽车、爱奇艺跌超4%,百度、B站跌超2%,蔚来跌超1%。

12分钟前

我国载人登月任务已全面进入初样研制阶段

中国载人航天工程总设计师周建平21日在深圳召开的第六届载人航天学术大会上表示,我国载人月球探测工程载人登月任务已经完成了前期的关键技术攻关和深化论证,目前全面进入了初样研制阶段。“目前,长征十号运载火箭、梦舟载人飞船、揽月月面着陆器、载人月球车等初样产品正在紧张研制过程中。不少初样产品已经研制出来,正在进行相关测试。”周建平说。(新华社)

12分钟前

李彦宏:百度将于2025年初发布新版大模型

36氪获悉,在百度2024年第三季度财报电话会上,百度创始人、董事长兼首席执行官李彦宏透露,百度将于2025年初发布文心大模型的新版本,以巩固在基础模型上的领先优势。李彦宏表示,11月,文心大模型日均调用量达15亿,日均处理Tokens文本超1.7万亿。相较一年前首次披露的5000万次日均调用量,增长30倍。

12分钟前

本页详细列出关于童年时光ChildLife的品牌信息,含品牌所属公司介绍,童年时光ChildLife所处行业的品牌地位及优势。
咨询